Inhibition of SGLT-2 blocks the reabsorption of glomerular-filtered glucose (and sodium) in the renal proximal tubular segment, a mechanism used to reduce hyperglycemia in patients with type 2 diabetes mellitus [2]. Here, SLC5A2 is linked to type 2 diabetes mellitus.